Preladenant, a novel adenosine A2A receptor antagonist for the potential treatment of parkinsonism and other disorders

IDrugs

Volumn 13, Issue 10, 2010, Pages 723-731

  Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; DESIPRAMINE; DOPAMINE; ISTRADEFYLLINE; LEVODOPA; PLACEBO; PRELADENANT; RASAGILINE; SCH 42081; UNCLASSIFIED DRUG;

AKATHISIA; ALKYLATION; AREA UNDER THE CURVE; BEHAVIOR; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERANCE; DYSKINESIA; FATIGUE; FORCED SWIMMING TEST; FOURIER TRANSFORM MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MEDICAL DECISION MAKING; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PSYCHOMOTOR RETARDATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY; TREATMENT CONTRAINDICATION; UNIFIED PARKINSON DISEASE RATING SCALE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; PARKINSONIAN DISORDERS; PYRIMIDINES; RATS; TRIAZOLES;

EID: 77957728136     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Exacerbation of parkinsonism by tacrine. Ott BR, Lannon MC CliN NEurOpHarMaCOl 1992 15 4 322-325
2. 2A receptor antagonist in MPTP-treated monkeys. Grondin R, Bedard PJ, Hadj-Tahara A, Gregoire L, Mori A, Kase H NEurOlOGY 1999 52 8 1673-1677
3. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y PSYCHOpHarMaCOlOGY 1999 147 1 90-95
4. 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P EXp NEurOl 2000 162 2 321-327
5. 2A receptor antagonist. Aoyama S, Kase H, Borrelli E J NEurOSCi 2000 20 15 5848-5852
6. 2A receptors. Svenningsson P, Le Moine C, Fisone G, Fredholm BB PROG NEUROBIOl 1999 59 4 355-396
7. 2A receptor antagonists, SCH 412348 and SCH 420814. Parker E, Bertorelli R, Cohen-Williams ME, Forlani A, Fredduzzi S, Greenlee W, Hao J, Higgins GA, Lachowicz J, Lu J, Neustadt B et al ABSTR SOC NEurOSCi 2006 36 Atlanta Abs 470.20/LL46
8. 2A receptor antagonist istradefylline (KW-6002) reduces "OFF" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM ANN NEUROL 2008 63 3 295-302
9. 2 family antagonists. Worden LT, Shahriari M, Farrar AM, Sink KS, Hockemeyer J, Muller CE, Salamone JD PSYCHOPHARMACOlOGY 2009 203 3 489-499
10. 2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J, Muller CE, Salamone JD PSYCHOPHARMACOLOGY 2009 204 1 103-112
11. 2A receptor agonist CGS-21680C.
12. 2A antagonist KW-6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: Comparisons with the muscarinic antagonist tropicamide. Betz AJ, Vontell R, Valenta J, Worden L, Sink KS, Font L, Correa M, Sager TN, Salamone JD NEurOSCiENCE 2009 163 1 97-108
13. Merck and Schering-Plough to complete merger today. Merck & Co Inc PRESS RELEASE 2009 November 04
14. 3 were > 1000 nM). The oral bioavailability of the hydrochloride salt of preladenant was 57%.
15. 2A antagonist preladenant in animal models of Parkinson's disease. Hodgson RA, Bertorelli R, Varty GB, Cohen-Williams ME, Forlani A, Fredduzzi S, Impagnatiello F, Nicolussi E, Ongini E, Parra LE, Parker EM et al MOV DiSOrD 2008 23 1 S88
16. Safety and tolerability profile of preladenant as an adjunct to L-DOPA in patients with Parkinson's disease. Pourcher E, Micheli F, Mok V, Onofrj M, Hauser RA, Huyck S, Wolski K, Cantillon M MOV DiSOrD 2009 24 S274
17. Positron emission tomography (PET) study of preladenant in healthy male subjects. Brooks DJ, Warrington S, Tendolkar A, Cutler DL, Hunter J MOV DiSOrD 2009 24 S257
18. 2A receptor antagonists for Parkinson's disease. Pinna A EXPERT OPIN INVESTIG DruGS 2009 18 11 1619-1631
19. 2A receptor antagonist preladenant on dyskinesia in moderate to severe Parkinson's disease: Post hoc analysis of dose-finding study. Huyck SB, Wolski K, Cantillon M MOV DISORD 2009 24 S1266
20. 2A antagonist, as an adjunct to levodopa for the treatment of Parkinson's disease. Hauser RA, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck SB, Wolski K, Cantillon M MOV DISORD 2009 24 S265 ••Results of a phase II clinical trial assessing preladenant in L-DOPA-treated patients (n = 253) with moderate-to-severe parkinson's disease. preladenant met its major endpoints by reducing OFF time and increasing ON time without worsening dyskinesias.
21. Effects of age and gender on preladenant pharmacokinetics in healthy subjects. Cutler DL, Tendolkar A, Hunter J MOV DIUORD 2009 24 S259-S260
22. 2A receptor antagonist under stressed conditions by LC-MS and FT tandem MS analysis. Zhang LK, Pramanik BN J MASS SPECTROM 2010 45 2 146-156
23. 2A receptor antagonists on haloperidol-induced movement disorders in primates. Varty GB, Hodgson RA, Pond AJ, Grzelak ME, Parker EM, Hunter JC PSYCHOPHARMACOLOGY 2008 200 3 393-401
24. 2A receptor antagonist programme for Parkinson's disease continues with next generation compound. Vernalis plc PRESS RElEASE 2010 July 16
25. 2A receptor antagonist under stressed conditions by LC tandem MS analysis. Zhang LK, Pramanik BN MiDDLE ATLANTIC REGIONAl MEET ACS 2008 40 May 17-21 Abs 221
26. 2A receptor antagonist for the treatment of Parkinson's disease: SCH 420814. Neustadt B, Hao J, Lindo N, Greenlee WJ, Stamford AW, Ongini E, Hunter J, Monopoli A, Bertorelli R, Fredduzzi S, Impagnatiello F et al ACS 2006 231 March 26-30 Abs MEDI 204
27. 2A antagonist. Exploring Parkinson's disease and beyond. Hunter JC TARGETING ADENOSINE A2A RECEPTORS PARKINSON'S DIS 2006 May 17-19
28. 2A receptor antagonists. Boyle CD, Shah U, Chackalamannil S, Neustadt B, Lindo N, Foster C, Arik L, Zhai Y, Lachowicz JE, Ng K, Wang S et al TARGETING ADENOSiNE A2A RECEPTORS PARKINSON'S DIS 2006 May 17-19 Abs P-1
29. 2A adenosine receptor antagonists. Lachowicz J, Zhai Y, Kwee L, Arik L, Hao J, Neustadt B, Greenlee W, Hunter J, Foster C TARGETING ADENOSINE A2A RECEPTORS PARKINSON'S DIS 2010 May 17-19 Abs P-2
30. 2A receptor antagonists: Triazolo[1, 5-c]pyrimidines. Liu H, Neustadt B, Foster C, Arik L, Lachowicz J, Bertorelli R, Fredduzzi S, Ng K, Stamford A, Greenlee W TARGETING ADENOSINE A2A RECEPTORS PARKINSON'S DiS 2006 May 17-19 Abs P-4
31. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of l-DOPA). Hornykiewicz O Br MED Bull 1973 29 2 172-178
32. Relationship between animal models and clinical parkinsonism. Marsden C, Duvoisin R, Jenner P, Parkes J, Pycock C, Tarsy D ADV NEUROlL 1975 9 165-175
33. Primate models of movement-disorders of basal ganglia origin. DeLong MR TRENDS NEurOSCi 1990 13 7 281-285
34. Tremulous jaw movements in rats: A model of parkinsonian tremor. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A PROG NEUROBIOl 1998 56 6 591-611
35. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K TRENDS NEurOSCi 1997 20 10 482-487
36. Adenosine/dopamine interaction: Implications for the treatment of Parkinson's disease. Ferre S, Popoli P, Gimenez-Llort L, Rimondini R, Muller CE, Stromberg I, Ogren O, Fuxe K PARKINSONISM RELAT DISORD 2001 7 3 235-241
37. Dopamine/adenosine interactions related to locomotion and tremor in animal models: Possible relevance to parkinsonism. Salamone JD, Ishiwari K, Betz AJ, Farrar AM, Mingote SM, Font L, Hockemeyer J, Muller CE, Correa M PARKINSONISM RELAT DISORD 2008 14 Suppl 2 S130-S134
38. 2 receptor knockout mice. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hacket E, Fink JS, Low MJ, Ongini E et al PROC NATl ACAD SCI USA 2001 98 4 1970-1975
39. 2 dopamine receptors in rat striatum. Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM, Reppert SM MOL BraiN RES 1992 14 3 186-195
40. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. Hettinger BD, Lee A, Linden J, Rosin DL J COMp NEUROL 2001 431 3 331-346
41. 2A receptors with positron emission tomography. Wang WF, Ishiwata K, Nonaka H, Ishii SI, Kiyosawa M, Shimada JI, Suzuki F, Senda M NUCL MED BiOl 2000 27 6 541-546
42. Immunocytochemistry studies of basal ganglia adenosine A2A receptors in rat and human tissue. Vontell R, Segovia KN, Betz AJ, Mingote S, Goldring K, Cartun RW, Salamone JD J HISTOTECHNOl 2010 33 41-47
43. 2A receptors and basal ganglia physiology. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S PROG NEUROBIOl 2007 83 5 277-292
44. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Ferre S PSYCHOPHARMACOlOGY 1997 133 2 107-120
45. 2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Ferre S, Ciruela F, Canals M, Marcellino D, Burgueno J, Casado V, Hillion J, Torvinen M, Fanelli F, de Benedetti P, Goldberg SR et al PARKINSONISM RELAT DISORD 2004 10 5 265-271
46. 2 receptor interactions: Implications for the function of G protein-coupled receptors. Ferre S, Quiroz C, Woods AS, Cunha R, Popoli P, Ciruela F, Lluis C, Franco R, Azdad K, Schiffmann SN CURR PHARM DESiGN 2008 14 15 1468-1474
47. 2A receptor signaling: Relevance for striatal function and Parkinson's disease. Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Torvinen M, Tinner-Staines B, Staines W, Rosin D, Terasmaa A, Popoli P et al NEUROLOGY 2003 61 11 Supplement 6 S19-S23
48. 2A adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Wardas J, Konieczny J, Lorenc-Koci E SYNAPSE 2001 41 2 160-171
49. 2A receptors in the caudate putamen of rats. Hauber W, Neuscheler P, Nagel J, Muller CE EUR J NEUROSCI 2001 14 8 1287-1293
50. 2A antagonists: Implications for parkinsonism. Salamone JD, Betz AJ, Ishiwari K, Felsted J, Madson L, Mirante B, Clark K, Font L, Korbey S, Sager TN, Hockemeyer J et al FRONT BIOSCI 2008 13 3594-3605
51. 2A antagonist KF 17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: Possible relevance to parkinsonism. Correa M, Wisniecki A, Betz A, Dobson DR, O'Neill MF, O'Neill MJ, Salamone JD BEHAV BRAIN RES 2004 148 1-2 47-54
52. 2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. Ishiwari K, Madson LJ, Farrar AM, Mingote SM, Valenta JP, DiGianvittorio MD, Frank LE, Correa M, Hockemeyer J, Muller C, Salamone JD BEHAV BRAIN RES 2007 178 2 190-199
53. Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity. Collins LE, Galtieri DJ, Collins P, Jones SK, Port RG, Paul NE, Hockemeyer J, Muller CE, Salamone JD BEHAV BRAIN RES 2010 211 2 148-155
54. Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of parkinsonism: Tremorolytic effects of pergolide, ropinirole and CY 208-243. Salamone JD, Carlson BB, Rios C, Lentini E, Correa M, Wisniecki A, Betz A BEHAV BRAIN RES 2005 156 2 173-179
55. 2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specifc striatal regions. Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M EXP NEUROL 2004 189 1 182-188
56. 1 antagonist DPCPX. Collins LE, Galtieri DJ, Brennum LT, Sager TN, Hockemeyer J, Mueller CE, Hinman JR, Chrobak JJ, Salamone JD PHARMACOl BIOCHEM BEHAV 2010 94 4 561-569
57. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, Chase TN EXP NEUROl 2003 184 1 285-294
58. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Morelli M, Pinna A NEUROlLSCI 2001 22 1 71-72
59. 2A receptor blockade plus L-DOPA in dopamine-denervated rats. Carta AR, Pinna A, Cauli O, Morelli M SYNAPSE 2002 44 3 166-174
60. 2A receptor antagonist, for the treatment of Parkinson's disease. Jenner P EXPERT OpIN iNVESTiG DruGS 2005 14 6 729-738
61. 2A receptors and Parkinson's disease. Morelli M, Carta AR, Jenner P HANDB EXP PHARMACOL 2009 193 589-615
62. When do levodopa motor fluctuations first appear in Parkinson's disease? Stocchi F, Jenner P, Obeso JA Eur NEurOl 2010 63 5 257-266
63. "ON-OFF" effects in patients with Parkinson's disease on chronic levodopa therapy. Marsden CD, Parkes JD LANCET 1976 1 7954 292-296
64. Vipadenant (V2006/BIIB014) is currently being developed as a potential new treatment for Parkinson's disease by our partner Biogen Idec. Vernalis COMPANY WORLD WIDE WEB SITE 2002
65. The role of dopamine/adenosine interactions in the brain circuitry regulating effort-related decision making: Insights into pathological aspects of motivation. Salamone JD, Correa M, Farrar AM, Nunes EJ, Collins LE FUTURE NEUROLOGY 2010 5 377-392
66. 2A agonist, on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats. Wardas J, Konieczny J, Pietraszek M PSYCHOPHARMACOlOGY 2003 168 3 299-306
67. Fatigue in Parkinson's disease: A review. Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, Lou JS, Marsh L, Nail L, Shulman L, Taylor CB MOV DISORD 2007 22 3 297-308
68. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Salamone JD, Correa M, Farrar A, Mingote SM PSYCHOPHARMACOLOGY 2007 191 3 461-482
69. 2 antagonism. Salamone JD, Farrar AM, Font L, Patel V, Schlar DE, Nunes EJ, Collins LE, Sager TN BEHAV BRAIN RES 2009 201 1 216-222
70. Biochemical and functional organization of the basal ganglia. Young AB, Penney JB PARKINSONS DISEASE AND MOVEMENT DiSOrDErS (EDS: JaNKOWiC J, TOlOSA E) 2006 Williams & Wilkins, Baltimore, MD, USA 5th Edition 1-12
71. Nucleus accumbens dopamine and the forebrain circuitry involved in behavioral activation and effort-related decision making: Implications for understanding anergia and psychomotor slowing in depression. Salamone JD, Correa M, Mingote SM, Weber SM, Farrar AM CURR PSYCHIATRY REV 2006 2 267-280
72. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM MOV DISORD 2008 23 15 2177-2185
73. 2A antagonists, and Parkinson's disease. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF PARKINSONISM RELAT DISORD 2009 15 6 406-413
74. 2 antagonism. Nunes EJ, Randall PA, Santerre JL, Given AB, Sager TN, Correa M, Salamone JD NEUROSCIENCE 2010 170 1 268-280
75. Merck pipeline July 30, 2010. Merck & Co Inc COMPANY WORLD WIDE WEB SITE 2010 July 30